Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with somatoform disorders

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Brettschneider, Christian ^a   König, Hans Helmut ^a   Herzog, Wolfgang ^b   Kaufmann, Claudia ^b   Schaefert, Rainer ^b   Konnopka, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

EQ 5D; Medically unexplained symptoms; Quality of life; Responsiveness; Somatoform disorders; Validity

Indexed keywords

ADULT; ARTICLE; CONSTRUCT VALIDITY; EQ 5D; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT HEALTH QUESTIONNAIRE 15; PATIENT HEALTH QUESTIONNAIRE 9; PSYCHOMETRY; QUALITY OF LIFE; SHORT FORM 36; SOMATOFORM DISORDER; VALIDITY; VISUAL ANALOG SCALE; WHITELEY INDEX 7;

FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PSYCHOLOGICAL TESTS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOMATOFORM DISORDERS;

EID: 84872108336     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-3     Document Type: Article

References (49)

1. Food and Drug Administration Guidance to the industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009, Rockville: Food and Drug Administration, Food and Drug Administration.
2. Drummond MF. ÓBrien B, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes 1997, Oxford, UK: Oxford University Press, 3539663, 23316486.
3. Gold M, Siegel J, Russel L, Weinstein M. Cost-effectiveness in health and medicine 1996, New York: Oxford University Press.
4. Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review Int J Technol Assess Health Care 2006, 22:235-241.
5. König HH, Ulshöfer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002, 14(11):1205-1215. 10.1097/00042737-200211000-00008, 12439115.
6. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res 2005, 14:95-105. 10.1007/s11136-004-0614-4, 15789944.
7. Matza LS, Boye KS, Yurgin N. Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Health Qual Life Outcomes 2007, 5:47. 10.1186/1477-7525-5-47, 2042494, 17672906.
8. König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007, 22(3):177-187. 10.1016/j.eurpsy.2006.08.004, 17142014.
9. Öster C, Willebrand M, Dyster-Aas J, Kildal M, Ekselius L. Validation of the EQ-5D questionnaire in burn injured adults. Burns 2009, 35:723-732. 10.1016/j.burns.2008.11.007, 19297100.
10. König HH, Born A, Günther O, Matschinger H, Heinrich S, Riedel-Heller SG, Angermeyer MC, Roick C. Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual Life Outcomes 2010, 8:47. 10.1186/1477-7525-8-47, 2873595, 20444251.
11. International Statistical Classification of Diseases and Related Health Problems http://apps.who.int/classifications/apps/icd/icd10online/, International Statistical Classification of Diseases and Related Health Problems.
12. American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 1994, Washington: APA Press, 4, American Psychiatric Association.
13. Roca M, Gili M, Garcia-Garcia M, Salva J, Vives M, Comas CJ. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord 2009, 119(1-3):52-58.
14. Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004, 56(4):391-408. 10.1016/S0022-3999(03)00622-6, 15094023.
15. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and drepressive disorders. Br J Psychiatry 2004, 184:470-476. 10.1192/bjp.184.6.470, 15172939.
16. Schaefert R, Kaufmann C, Wild B, Schellberg D, Boelter R, Faber R, Szecsenyi J, Sauer N, Guthrie E, Herzog W. Specific Collaborative Group Intervention for Patients with Medically Unexplained Symptoms in General Practice (speciAL): A Cluster Randomized Controlled Trial. Psychother Psychosom (in Press) 2012,
17. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984, 2:187-193.
18. Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry 2010, 32:345-359. 10.1016/j.genhosppsych.2010.03.006, 20633738.
19. Fink P, Ewald H, Jensen J, Sorensen L, Engberg M, Holm M, Munk-Jorgensen P. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatizazion. J Psychosom Res 1999, 46(3):261-273. 10.1016/S0022-3999(98)00092-0, 10193917.
20. Christensen KS, Fink P, Toft T, Frostholm L, Ombol E, Olesen F. A brief case-finding questionnaire for common mental disorders: the CMDQ. Fam Pract 2005, 22(4):448-457. 10.1093/fampra/cmi025, 15814580.
21. Conradt M, Cavanagh M, Franklin J, Rief W. Dimensionality of the Whiteley Index: Assessment of Hypochondriasis in an Australian sample of primary care patients. J Psychosom Res 2006, 60:137-143. 10.1016/j.jpsychores.2005.07.003, 16439266.
22. Benedikt G, Schulmeister E, Sattel H, Schaefert R, Sauer N, Herzog W, Henningsen P. Somatic symptoms and illness worries in primary care - a study of 1751 general practice attenders. Z Psychiatr Psychol Psychother 2007, 55:21-29.
23. Schaefert R, Kaufmann C, Wild B, Schellberg D, Boelter R, Faber R, Szecsenyi J, Sauer N, Guthrie E, Herzog W. Specific Collaborative Group Intervention for Patients with Medically Unexplained Symptoms in General Practice: A Cluster Randomized Controlled Trial. Psychother Psychosom 2013, 82:106-119.
24. The Euroqol Group EuroQol* - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The Euroqol Group.
25. Dolan P. Modeling Valuations for EuroQol Health States. Med Care 1997, 35(11):1095-1108. 10.1097/00005650-199711000-00002, 9366889.
26. Greiner W, Claes C, Busschbach JJV, von der Schuldenburg J-MG. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005, 6:124-130. 10.1007/s10198-004-0264-z, 19787848.
27. Spitzer RL, Kroenke K, Williams JBW, Group PHQPCS. Validation and utility of a self-report Version of PRIME-MD: The PHQ Primary Care Study. JAMA 1999, 282(18):1737-1744. 10.1001/jama.282.18.1737, 10568646.
28. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a New Measure for Evaluating the severity of Somatic Symptoms. Psychosom Med 2002, 64:258-266.
29. Löwe B, Spitzer RL, Zipfel J, Herzog W. PHQ-D Geusndheitsfragebogen für Patienten; Manual und Kurzform. Volume 2 2002, Karlsruhe: Pfizer.
30. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med 2001, 16(9):606-613. 10.1046/j.1525-1497.2001.016009606.x, 1495268, 11556941.
31. Hanel H, Henningsen P, Herzog W, Sauer N, Schaefert R, Szecsenyi J, Löwe B. Depression, anxiety, and somatoform disorders: Vague or distinct categories in primary care? Results from a large cross-sectional study. J Psychosom Res 2009, 67:189-197. 10.1016/j.jpsychores.2009.04.013, 19686874.
32. Pilowsky I. Dimensions of Hypochondriasis. Br J Psychiatry 1967, 113:89-93. 10.1192/bjp.113.494.89, 6029373.
33. Hiller W, Rief W. Internationale Skalen für Hypochondrie. Deutschsprachige Adaptation des Whiteley-Index (WI) und der Illness Attitude Scales (IAS) 2004, Bern: Huber, 1.
34. Rief W, Hiller W, Geissner E, Fichtner MM. Hypochondriasis: Assessment and initial clinical results. Z Klin Psychol Psychother 1994, 23(1):34-42.
35. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual Framework and Item. Selection Med Care 1992, 30(6):473-483.
36. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: Preliminary results from the IQOLA Project. Soc Sci Med 1995, 41(10):1359-1366. 10.1016/0277-9536(95)00115-N, 8560303.
37. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Handanweisungen und Fragebögen 1998, Göttingen: Hogrefe.
38. Hoedeman R, Krol B, Blankenstein N, Koopmans PC, Groothoff JW. Severe MUPS in a sick-listed population: a cross-sectional study on prevalence, recognition, psychiatric co-morbidity and impairment. BMC Publ Health 2009, 9:440.
39. Hansen HS, Rosendal M, Oernboel E, Fink P. Are medically unexplained symptoms and functional disorders predictive for the illness course? A two-year follow-up on patients' health and health care utilisation. J Psychosom Res 2011, 71(1):38-44. 10.1016/j.jpsychores.2011.02.015, 21665011.
40. van Fenema EM, van der Wee NJ, Giltay EJ, den Hollander-Gijsman ME, Zitman FG. Vitality predicts level of guideline-concordant care in routine treatment of mood, anxiety and somatoform disorders. J Eval Clin Pract 2012, 18(2):441-448. 10.1111/j.1365-2753.2010.01593.x, 21091854.
41. Zonneveld LN, van Rood YR, Timman R, Kooiman CG, Van't Spijker A, Busschbach JJ. Effective group training for patients with unexplained physical symptoms: a randomized controlled trial with a non-randomized one-year follow-up. PLoS One 2012, 7:8.
42. Luo X, Capelleri J. A practical guide on incorporating and evaluating patient-reported outcomes in clinical trials. Clin Res Regul Aff 2008, 25(4):197-211.
43. König HH, Bernert S, Angermeyer MC. Health Status of the German Population: Results of a Representative Survey Using the EuroQol Questionnaire. Gesundheitswesen 2005, 67:173-182. 10.1055/s-2005-857991, 15789280.
44. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, Group MFP-ROCM. What is sufficient evidence for the reliability and validity of patient-reported outcome measures?. Value Health 2007, 10(Suppl 2):S94-S105.
45. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 2007, 16(4):717-723. 10.1007/s11136-006-9153-5, 17268927.
46. Garratt AM, Ruta DA, Abdalla MI, Russell IT. SF-36 health survey questionnaire: II. Responsiveness to changes in health status in four common conditions. Qual Health Care 1994, 3:186-192. 10.1136/qshc.3.4.186, 1055239, 10140232.
47. Cohen J. Statistical power analysis for behavioral sciences 1988, Hillsdale, NJ: Lawrence Earlbaum associates.
48. Kontodimopoulos N, Pappa E, Niakis D, Yfantopoulos J, Dimitrakaki C, Tountas Y. Validity of the EuroQol (EQ-5D) Instrument in a Greek General Population. Value Health 2008, 11(7):1162-1169. 10.1111/j.1524-4733.2008.00356.x, 18489492.
49. Baker R. Measuring change in health in general practice: a comparison of a simple transition question with the Nottingham Health Profile. Int J Qual Health Care 1998, 10(3):207-212. 10.1093/intqhc/10.3.207, 9661059.